- Home
- MPB vs MLYS Comparison
MPB vs MLYS Comparison
Compare MPB & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- MLYS
- Stock Information
- Founded
- MPB 1868
- MLYS 2019
- Country
- MPB United States
- MLYS United States
- Employees
- MPB N/A
- MLYS N/A
- Industry
- MPB Major Banks
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- MLYS Health Care
- Exchange
- MPB Nasdaq
- MLYS Nasdaq
- Market Cap
- MPB 525.0M
- MLYS 526.1M
- IPO Year
- MPB N/A
- MLYS 2023
- Fundamental
- Price
- MPB $29.19
- MLYS $10.21
- Analyst Decision
- MPB Buy
- MLYS Strong Buy
- Analyst Count
- MPB 2
- MLYS 2
- Target Price
- MPB $36.00
- MLYS $30.00
- AVG Volume (30 Days)
- MPB 71.0K
- MLYS 263.5K
- Earning Date
- MPB 01-22-2025
- MLYS 03-20-2025
- Dividend Yield
- MPB 2.74%
- MLYS N/A
- EPS Growth
- MPB 14.41
- MLYS N/A
- EPS
- MPB 2.91
- MLYS N/A
- Revenue
- MPB $173,416,000.00
- MLYS N/A
- Revenue This Year
- MPB N/A
- MLYS N/A
- Revenue Next Year
- MPB $19.26
- MLYS N/A
- P/E Ratio
- MPB $10.05
- MLYS N/A
- Revenue Growth
- MPB 4.93
- MLYS N/A
- 52 Week Low
- MPB $19.20
- MLYS $8.58
- 52 Week High
- MPB $33.87
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- MPB 46.67
- MLYS 44.53
- Support Level
- MPB $30.02
- MLYS $9.57
- Resistance Level
- MPB $31.36
- MLYS $10.79
- Average True Range (ATR)
- MPB 0.75
- MLYS 0.64
- MACD
- MPB 0.16
- MLYS 0.11
- Stochastic Oscillator
- MPB 45.23
- MLYS 63.98
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.